D.E. Shaw & Co’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

D.E. Shaw & Co’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-797,567	Closed	-$85.6M	–	4747
2023 Q1	$85.6M	Buy	797,567 +72,338	+10%	+$8.33M	0.09%	259
2022 Q4	$79.8M	Buy	725,229 +563,848	+349%	+$36.6M	0.09%	261
2022 Q3	$9.52M	Buy	161,381 +117,360	+267%	+$5.37M	0.01%	1390
2022 Q2	$1.24M	Sell	44,021 -24,882	-36%	-$721K	﹤0.01%	3474
2022 Q1	$2.6M	Buy	68,903 +52,432	+318%	+$2.07M	﹤0.01%	3039
2021 Q4	$651K	Buy	+16,471	New	+$516K	﹤0.01%	4245

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

D.E. Shaw & Co's RXDX Position: Q2 2023 in Review

D.E. Shaw & Co sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 797,567 shares — an estimated $85.6M sold.

D.E. Shaw & Co first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $85.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

D.E. Shaw & Co reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
D.E. Shaw & Co sold 797,567 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $85.6M.
D.E. Shaw & Co first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
D.E. Shaw & Co's Prometheus Biosciences, Inc. Common Stock position peaked at $85.6M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.